● Recruiting

Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer

Condition: Cancer of Cervix · Apoptosis · Sponsor: Centre Hospitalier Universitaire de Nīmes

PhaseN/A

Planned participants180

Who can joinFemale, 18 Years to no upper limit

Healthy volunteersNo

About this study

Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence rate at 24 months.

This description comes directly from the study's public registry record.

Talk to the study team

Frédéric FITENI, Dr. · +334.34.03.46.69 · frederic.fiteni@chu-nimes.fr

Anissa MEGZARI · +33466684236 · drc@chu-nimes.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHU de Nîmes

Nîmes, Gard, France

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06147960